Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Thorac Cardiovasc Surg ; 125(5): 1022-9, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12771874

RESUMO

OBJECTIVE: Esmolol, an ultra-short-acting beta-blocker, is known to attenuate myocardial ischemia-reperfusion injury. The aim of this study was to compare the effects of esmolol and potassium on myocardial metabolism during continuous normothermic retrograde blood cardioplegia. METHODS: Forty-one patients operated on for isolated aortic valve stenosis were randomly assigned to continuous coronary infusion with either potassium or esmolol during cardiopulmonary bypass. Myocardial metabolism was assessed by measuring the transmyocardial gradient of oxygen content indexed to left ventricular mass of glucose, lactate, and nitric oxide. To do so, blood samples were simultaneously withdrawn upstream (in the cardioplegia line) and downstream of the myocardium (in the left coronary ostium) 10 and 30 minutes after aortic crossclamping. RESULTS: Although the cardioplegia flow rate and pressure were similar, esmolol markedly reduced the transmyocardial gradient of oxygen content indexed to left ventricular mass compared with potassium: 13 +/- 6 vs 20 +/- 6 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 10 minutes and 16 +/- 8 vs 24 +/- 8 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 30 minutes (P =.009). Coronary glucose and lactate transmyocardial gradients were similar in both groups, indicating adequate myocardial perfusion in all patients at all times. In addition, during retrograde cardioplegia, esmolol showed a lower nitric oxide release compared with that caused by potassium (39 +/- 49 micro mol x L(-1) for potassium vs 14 +/- 8 micro mol x L(-1) for esmolol at 10 minutes and 39 +/- 47 micro mol x L(-1) for potassium vs 6 +/- 8 micro mol x L(-1) for esmolol at 30 minutes, P =.05). However, hemodynamic parameters and plasma troponin I levels remained unchanged postoperatively between the 2 types of cardioplegia. CONCLUSION: Esmolol provides potent myocardial protection in hypertrophied hearts, at least in part, by reducing myocardial oxygen metabolism.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Estenose da Valva Aórtica/cirurgia , Soluções Cardioplégicas , Isquemia Miocárdica/prevenção & controle , Potássio/uso terapêutico , Propanolaminas/uso terapêutico , Antagonistas Adrenérgicos beta/farmacologia , Idoso , Estenose da Valva Aórtica/complicações , Soluções Cardioplégicas/efeitos adversos , Ponte Cardiopulmonar , Humanos , Hipertrofia Ventricular Esquerda/complicações , Ácido Láctico/sangue , Tempo de Internação , Pessoa de Meia-Idade , Contração Miocárdica/efeitos dos fármacos , Isquemia Miocárdica/etiologia , Consumo de Oxigênio/efeitos dos fármacos , Potássio/farmacologia , Propanolaminas/farmacologia , Resultado do Tratamento , Troponina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...